Cardiovascular drug development has long circled the same targets: cholesterol and blood pressure. Rosera is moving to break that pattern. The company’s lead molecule, ravnoflast, is built to reach deep into tissues and the brain, aiming to shut down chronic inflammation that lingers even after standard risk factors are managed. The upcoming Phase 3 trial in peripheral artery disease (PAD) will test whether this approach can finally shift outcomes for millions who remain at risk despite current therapies.
CEO Geoff McDonough doesn’t mince words. He says the science behind inflammation’s role in heart disease is no longer in doubt. The real hurdle is building a drug that works where it matters. He points to the early work of Harvard’s Paul Ridker and Peter Libby, who tracked unexplained cardiac events in patients without classic risk factors, and to the Jupiter and CANTOS trials that put inflammation at the center of the conversation. Rosera’s pitch: industrialize that insight with a molecule designed for tissue-level action. “Chronic inflammation is detectable and is present in our bloodstreams. But where chronic inflammation causes disease and damage is when it's active in our tissues, in our brains, in the walls of our arteries, in our livers, in our kidneys, in our skeletal muscles.”
In the RESOLVE-2 trial, ruvonoflast was evaluated in combination with semaglutide in a randomized, double-blind, placebo-controlled multicenter study involving 82 participants, with safety and tolerability as primary endpoints.
Engineering for tissue and brain penetration
Ravnoflast’s technical edge comes from its ability to leave the bloodstream and build up in tissues where inflammation does its damage. Earlier NLRP3 inhibitors like MCC950 showed strong activity in blood but rarely made it into tissue, limiting their effect. Scientific founder Alan Watt tackled this by inventing new chemotypes and pharmacophores that bind NLRP3 tightly and move quickly from blood to tissue. The result: a volume of distribution of 15 L, three times the usual 5 L for this drug class, and a brain-to-plasma ratio (Kpu) of 1.5, the highest seen for any NLRP3 inhibitor. That means ravnoflast reaches higher free drug levels in the brain than in the periphery, a technical leap that could matter for neuroinflammatory disease as well.
Ravnoflast is an oral small molecule that binds NLRP3 subunits and blocks inflammasome assembly. Its design is deliberate: it stays electrically neutral in the bloodstream to cross membranes, then switches to a polar form inside inflammatory cells, trapping it where it’s needed. McDonough calls this a multiplier for the drug’s anti-inflammatory effect, as it concentrates in cells like monocytes and microglia. The target is the inflammasome complex—the “spark that lights the fire”—which triggers downstream factors including IL-18 and IL-1 beta.
Peripheral artery disease as the commercial beachhead
Rosera’s decision to start with PAD is a calculated move. The numbers are hard to ignore: 20 million PAD patients in the US, 85% with high residual inflammatory risk, $21 billion in annual healthcare costs, and no new PAD pathobiology approvals in 25 years. Most therapies since 1999 have focused only on limb-threatening disease, leaving most patients without disease-modifying options. McDonough says ravnoflast is meant as an add-on to existing therapies—statins and GLP-1 drugs—not a replacement. Phase 2 trials allowed all co-administered medicines, and the safety profile so far supports combination use.
Recent updates show that the candidate now called ruvonoflast (formerly NT-0796) is being advanced by Rezera, not Rosera, and is already in a Phase 3 program for PAD. The company has announced that the REVEAL-PAD study is underway, but these data are dated to 2026 and should be checked against clinical trial registries for the latest status.
The company reported that the combination of ruvonoflast with semaglutide produced a statistically significant additional reduction in high-sensitivity C-reactive protein compared to semaglutide alone, with the difference between groups maintained throughout the study. Absolute values and confidence intervals were not disclosed in the available summary.
McDonough draws a line between biomarker shifts and real-world benefit. Biomarkers like hsCRP and IL-6 show pharmacodynamic activity, but they don’t always predict patient outcomes. “Blood-based biomarkers in the main, and specifically in inflammation, do not reflect the inflammation status of the tissues. You routinely find patients who with imaging have profound inflammation of the cardiac wall or of the brain or of the liver and have quite normal hsCRP.” For Rosera, the endpoints that matter are patient-centered: walking distance, quality of life, and disease progression. Biomarkers are for early-phase trials; outcomes drive value.
Pipeline segmentation and capital strategy
Rosera isn’t putting all its chips on one molecule. The company is also advancing trabzanoflast (NT0150), a next-generation NLRP3 inhibitor built for even higher brain penetration. Phase 1 is done, and cerebrospinal fluid data are expected soon. The plan is to segment development by tissue compartment and disease biology: ravnoflast for systemic and some CNS indications, trabzanoflast for those needing maximal brain exposure. McDonough is clear that different NLRP3 inhibitor profiles will fit different diseases, and combination therapy will matter over time. “I don't think this is going to be a Lord of the Rings moment where there'll be one ring to rule them all.”
On the financial side, Rosera’s cash runway stretches into 2027, but a Phase 3 program will need new capital. McDonough describes a “mosaic” approach: equity markets and pharma partnerships assembled over the next year or two. The company has already run four clinical trials of ravnoflast, with more than 400 patients exposed, including the largest and longest Phase 2 study for an NLRP3 inhibitor. A fifth study combining ravnoflast with semaglutide is ongoing, and one completed trial remains unreported. This clinical dataset supports the planned Phase 3 launch in early 2027.
According to company statements, the safety profile of the ruvonoflast and semaglutide combination matched previous data for both drugs, though the full list of adverse events and their frequencies was not disclosed. The company says the RESOLVE-2 results support further development of ruvonoflast for PAD and highlight the potential of NLRP3 inhibition to address residual inflammatory risk. This remains the developer’s position, not an independent regulatory or efficacy assessment.
Rosera wants to make NLRP3 inhibition a standard of care for the silent driver of disease progression—elevated residual inflammatory risk—rather than a niche mechanism. The company is betting that tissue-level NLRP3 inhibition can deliver clinical benefit in PAD without the infection risk that has limited earlier inflammation drugs to rare diseases. The next milestones are the Phase 3 readout, the upcoming trabzanoflast cerebrospinal fluid data, and the outcome of Rosera’s capital mosaic. For a look at how other companies are handling late-stage clinical development in tough indications, see our reported earlier on Artiva’s AlloNK cell therapy in rheumatoid arthritis.
